MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
MaxCyte (Nasdaq: MXCT; LSE: MXCT) and Kamau Therapeutics have entered a strategic platform license agreement. Kamau gains non-exclusive rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform for research, clinical, and commercial purposes. In return, MaxCyte will receive annual licensing fees and program-related revenue.
Kamau, a clinical-stage company, is developing gene correction therapies using homology-directed repair (HDR) editing. Their lead program, nula-cel, targets sickle cell disease (SCD). This partnership aims to optimize Kamau's clinical manufacturing process and expedite the development of potential cures for genetic diseases.
MaxCyte's ExPERT™ platform offers high transfection efficiency, scalability, and enhanced functionality for complex cell engineering. This marks MaxCyte's 29th clinical/commercial partnership, contributing to its pre-commercial milestone revenue stream.
MaxCyte (Nasdaq: MXCT; LSE: MXCT) e Kamau Therapeutics hanno firmato un accordo di licenza per una piattaforma strategica. Kamau ottiene diritti non esclusivi per utilizzare la tecnologia Flow Electroporation® di MaxCyte e la piattaforma ExPERT™ per scopi di ricerca, clinici e commerciali. In cambio, MaxCyte riceverà canoni di licenza annuali e ricavi correlati ai programmi.
Kamau, un'azienda in fase clinica, sta sviluppando terapie di correzione genica utilizzando l'editing tramite riparazione omologa (HDR). Il loro programma principale, nula-cel, si concentra sulla malattia falciforme (SCD). Questa partnership mira a ottimizzare il processo di produzione clinica di Kamau e accelerare lo sviluppo di potenziali cure per le malattie genetiche.
La piattaforma ExPERT™ di MaxCyte offre alta efficienza di trasfezione, scalabilità e funzionalità avanzate per l'ingegneria cellulare complessa. Questo segna la 29esima partnership clinica/commerciale di MaxCyte, contribuendo al suo flusso di entrate derivanti da traguardi pre-commerciali.
MaxCyte (Nasdaq: MXCT; LSE: MXCT) y Kamau Therapeutics han firmado un acuerdo de licencia de plataforma estratégica. Kamau obtiene derechos no exclusivos para utilizar la tecnología Flow Electroporation® de MaxCyte y la plataforma ExPERT™ con fines de investigación, clínicos y comerciales. A cambio, MaxCyte recibirá tasas de licencia anuales y ingresos relacionados con programas.
Kamau, una empresa en etapa clínica, está desarrollando terapias de corrección genética utilizando edición por reparación dirigida por homología (HDR). Su programa principal, nula-cel, está dirigido a la enfermedad de células falciformes (SCD). Esta asociación tiene como objetivo optimizar el proceso de fabricación clínica de Kamau y acelerar el desarrollo de posibles curas para enfermedades genéticas.
La plataforma ExPERT™ de MaxCyte ofrece alta eficiencia de transfección, escalabilidad y funcionalidad mejorada para la ingeniería celular compleja. Esta es la 29ª asociación clínica/comercial de MaxCyte, que contribuye a su flujo de ingresos por hitos pre-comerciales.
MaxCyte (Nasdaq: MXCT; LSE: MXCT)와 Kamau Therapeutics가 전략적 플랫폼 라이센스 계약을 체결했습니다. Kamau는 연구, 임상 및 상업적 목적을 위해 MaxCyte의 Flow Electroporation® 기술과 ExPERT™ 플랫폼을 사용할 수 있는 비독점 권리를 부여받습니다. 그 대가로 MaxCyte는 연간 라이센스 수수료 및 프로그램 관련 수익을 받게 됩니다.
임상 단계에 있는 회사인 Kamau는 동종 이식 수리(HDR) 편집을 사용하여 유전자 교정 치료제를 개발하고 있습니다. 그들의 주요 프로그램인 nula-cel은 격리 세포병(SCD)를 대상으로 합니다. 이 파트너쉽의 목표는 Kamau의 임상 제조 과정을 최적화하고 유전 질환의 잠재적 치료 개발을 가속화하는 것입니다.
MaxCyte의 ExPERT™ 플랫폼은 복잡한 세포 공학을 위한 높은 전이 효율성, 확장성 및 향상된 기능성을 제공합니다. 이는 MaxCyte의 29번째 임상/상업적 파트너십으로, 사전 상업적 이정표 수익 흐름에 기여하고 있습니다.
MaxCyte (Nasdaq: MXCT; LSE: MXCT) et Kamau Therapeutics ont conclu un accord de licence de plateforme stratégique. Kamau obtient des droits non exclusifs d'utilisation de la technologie Flow Electroporation® de MaxCyte et de la plateforme ExPERT™ à des fins de recherche, cliniques et commerciales. En retour, MaxCyte recevra des redevances de licence annuelles et des revenus liés aux programmes.
Kamau, une entreprise en phase clinique, développe des thérapies de correction génique utilisant la réparation dirigée par homologie (HDR). Leur programme phare, nula-cel, cible la maladie des cellules falciformes (SCD). Ce partenariat vise à optimiser le processus de fabrication clinique de Kamau et à accélérer le développement de traitements potentiels pour les maladies génétiques.
La plateforme ExPERT™ de MaxCyte offre une haute efficacité de transfection, une évolutivité et une fonctionnalité améliorée pour l'ingénierie cellulaire complexe. Cela marque la 29e partenariat clinique/commercial de MaxCyte, contribuant à son flux de revenus liés aux jalons pré-commerciaux.
MaxCyte (Nasdaq: MXCT; LSE: MXCT) und Kamau Therapeutics haben eine strategische Plattform-Lizenzvereinbarung getroffen. Kamau erhält nicht-exklusive Rechte zur Nutzung von MaxCytes Flow Electroporation®-Technologie und ExPERT™-Plattform für Forschungs-, klinische und kommerzielle Zwecke. Im Gegenzug erhält MaxCyte jährliche Lizenzgebühren und programmspezifische Einnahmen.
Kamau, ein Unternehmen in der klinischen Phase, entwickelt Genkorrekturtherapien mittels Homologe-reparierender (HDR) Bearbeitung. Ihr Hauptprogramm, nula-cel, zielt auf Sichelzellenkrankheit (SCD) ab. Diese Partnerschaft hat das Ziel, den klinischen Herstellungsprozess von Kamau zu optimieren und die Entwicklung potenzieller Heilmittel für genetische Erkrankungen zu beschleunigen.
Die ExPERT™-Plattform von MaxCyte bietet hohe Transfektions-effizienz, Skalierbarkeit und verbesserte Funktionalität für komplexe Zelltechnik. Dies ist die 29. klinische/kommerzielle Partnerschaft von MaxCyte, die zu ihrem vor-kommerziellen Einnahmenstrom beiträgt.
- MaxCyte secures a new strategic platform license agreement, expanding its revenue sources
- The partnership provides MaxCyte with annual licensing fees and program-related revenue
- This marks MaxCyte's 29th clinical/commercial partnership, strengthening its market position
- The agreement potentially accelerates the development of gene therapies for serious genetic diseases
- None.
This strategic partnership between MaxCyte and Kamau Therapeutics marks a significant advancement in cell therapy development for genetic diseases. Kamau's access to MaxCyte's Flow Electroporation® technology and ExPERT™ platform could accelerate the progress of their homology-directed repair (HDR) gene correction technology, particularly for sickle cell disease (SCD).
The deal structure, involving annual licensing fees and program-related revenue for MaxCyte, suggests a potentially lucrative long-term collaboration. This agreement, being MaxCyte's 29th clinical/commercial partnership, reinforces their position as a leading enabler in the cell therapy space.
For investors, this partnership highlights MaxCyte's growing influence in the biotech sector and its ability to generate recurring revenue streams. The collaboration also underscores the increasing importance of non-viral delivery methods in gene therapy, potentially opening up new market opportunities for MaxCyte's technology.
Kamau Therapeutics' focus on homology-directed repair (HDR) editing represents a significant leap forward in gene therapy. Unlike first-generation CRISPR-Cas9 technology that only cuts DNA, HDR provides a template for DNA repair, potentially offering more precise and durable genetic modifications.
The application of this technology to sickle cell disease (SCD) through Kamau's lead program, nula-cel, is particularly promising. SCD affects millions worldwide and currently lacks a cure. A successful one-time curative therapy could revolutionize treatment paradigms and significantly improve patient outcomes.
MaxCyte's electroporation technology could play a important role in overcoming manufacturing challenges associated with cell therapies. By enabling more efficient and scalable gene editing, it may accelerate the translation of Kamau's innovative approach from bench to bedside, potentially benefiting patients sooner.
Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology
ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) agreement.
Under the terms of the agreement, Kamau obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue.
Kamau is a clinical-stage, next-generation gene correction company harnessing high efficiency targeted gene integration to develop a new class of therapies with the aim to cure a wide range of serious and life-threatening diseases, such as sickle cell disease (SCD). The company’s platform, which is founded on homology-directed repair (HDR) editing, builds on first generation CRISPR-Cas9 technology by not only cutting DNA but providing a template to repair DNA. HDR now forms the basis for Kamau’s lead investigational program, nula-cel, which is in clinical development for SCD.
“Bringing this groundbreaking gene therapy research into the clinic requires a robust manufacturing process and the ability to scale,” said Maher Masoud, President and CEO of MaxCyte. “By partnering with us, Kamau gains access to our commercially validated Flow Electroporation technology as well as technical, regulatory and scientific support. This enables them to optimize their clinical manufacturing process, mitigate risks and expedite the progression of their lead product candidate through clinical phases to deliver this potential cure to patients living with SCD.”
“HDR overcomes prior limitations in specificity, efficiency and durability of gene editing to offer broad potential for transforming human health outcomes through the delivery of one-time curative cell therapies,” said Matthew Porteus, MD, PhD, Co-Founder of Kamau. “Through our collaboration with MaxCyte and the use of their proven non-viral platform, our goal is to treat or cure a range of serious genetic diseases with unmet medical needs using homology-directed repair.”
MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically and commercially validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Kamau Therapeutics is MaxCyte’s 29th clinical/commercial partnership overall; each partnership generates pre-commercial milestone revenue, the vast majority of which includes program-related revenue.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.
About Kamau Therapeutics
Kamau Therapeutics is a clinical-stage, gene correction company dedicated to transforming the lives of patients with devastating genetic diseases through best-in-class, curative stem-cell therapies. Kamau stands apart through the unique capabilities of its next-generation gene correction platform that directly corrects genetic mutations with unprecedented precision: removing the pathologic mutation and replacing it with the healthy version. The company’s platform technology is based on the pioneering research of company co-founder Matthew Porteus, MD, PhD, and offers broad potential for transforming human health. Kamau’s lead clinical program, nulabeglogene autogedtemcel (nula-cel), previously developed by Graphite Bio, is the only hematopoietic stem-cell based therapy in clinical development for sickle cell disease (SCD) that precisely corrects the mutation in the beta-globin gene found in the sickled hemoglobin (HgbS) of SCD patients, restoring patient’s stem cells to normal adult hemoglobin (HgbA). Kamau plans to enroll additional patients with SCD in the Phase 1/2 clinical trial of nula-cel, for which it has received both fast track and orphan drug designations from the U.S. Food and Drug Administration (FDA). For more information, please visit kamautx.com and follow the company’s progress on its LinkedIn page.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Science
Jordan Vines
jvines@spectrumscience.com
+1 540-629-3137
Nominated Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
Kamau Contacts:
Kamau Therapeutics
Laura Henry
+1-415-980-0256
E: lhenry@kamautx.com
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.
Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 12, 2024, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 6, 2024. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
FAQ
What is the nature of the agreement between MaxCyte and Kamau Therapeutics?
How will MaxCyte (MXCT) benefit from this partnership?
What is Kamau Therapeutics developing using MaxCyte's technology?
How many clinical/commercial partnerships does MaxCyte (MXCT) now have?
